Groundbreaking data from Eli Lilly & Co. LLY has sparked a new conversation about obesity treatments, with their experimental drug, retatrutide, showing astonishing weight loss results, Bloomberg reports.
Unprecedented Weight Loss
Retatrutide has demonstrated remarkable efficacy in a mid-stage study, with most participants losing nearly a quarter of their body weight, and a subset losing over 30% after 48 weeks on a high dosage. The weight loss journey for some participants hasn’t plateaued yet, indicating potential for further weight reduction.
See Also: Move Over, Ozempic: Eli Lilly’s Retatrutide Is The New Weight Loss Champion
Setting New Standards
This breakthrough comes on the heels of Novo Nordisk’s game-changing weight-loss drug, Wegovy, which helped people lose approximately 15% of their body weight. Lilly’s tirzepatide followed, causing nearly 20% weight loss in a Phase 3 study. Now, retatrutide has raised the bar even higher.
Implications for Obesity Treatment
While the efficacy and safety of retatrutide need further validation in a larger trial, the potential level of weight loss could virtually eliminate the need for bariatric surgery for individuals with a BMI of 35 or more, according to BMO Capital Markets analyst Evan Seigerman.
See Also: Ozempic, But Without The Needles: Pharma Giants Rush To Bring Weight Loss Drugs In Pill Form
Metabolic Manipulation
Retatrutide’s effectiveness seems to stem from its unique approach to manipulating appetite-controlling hormones. It mimics GLP-1 and GIP hormones involved in insulin secretion, and also stimulates a third hormone, the glucagon receptor, found in the liver. This could be a key factor in the drug’s benefits.
Additional Health Benefits
Beyond weight loss, retatrutide has shown promising health impacts, such as a 20% reduction in LDL or “bad” cholesterol, and an over 80% decrease in liver fat levels. These results suggest that retatrutide could potentially tackle obesity, diabetes, and liver disease simultaneously.
Read Next: Is Ozempic Right For Your Weight Loss Goals?
Hi, I am the Benzinga Newsbot! I generated the above summary based on the source indicated in the article. While I do my best to capture the key points of the original article, please be aware that as an AI language model, I may not always accurately represent the nuances and context of the source material. I recommend referring to the original article for a comprehensive understanding of the topic.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.